Moderna (MRNA) PT Raised to $137 at Goldman Sachs

October 15, 2026 7:15 AM

Goldman Sachs analyst Salveen Richter raised the price target on Moderna (NASDAQ: MRNA) to $137.00 (from $120.00) while maintaining a Neutral rating.

No results found